From: Torczon, Richard <rtorczon@wsgr.com>
`Sent: Thursday, November 14, 2019 7:46 AM
`To: Trials <Trials@USPTO.GOV>
`Cc: Josh Griswold <griswold@fr.com>; Desai, Anish <anish.desai@weil.com>; IPR28328-0010IP1
`<IPR28328-0010IP1@fr.com>; Derryberry, Wes <wderryberry@wsgr.com>; Thomas, Tasha
`<tthomas@wsgr.com>; Carsten, Douglas <dcarsten@wsgr.com>; Guise, Jeff <JGuise@wsgr.com>;
`Dykhuis, Arthur <adykhuis@wsgr.com>; Steiner, Ellie <esteiner@wsgr.com>; Chu, Franklin
`<ychu@wsgr.com>; Westin, Lori <lwestin@wsgr.com>; Stafford, Nicole <nstafford@wsgr.com>;
`JWong@winston.com; PfizerIPRs@winston.com; Ansley, Sutton <sutton.ansley@weil.com>; Karl Renner
`<renner@fr.com>; John S. Goetz <Goetz@fr.com>; Matt Colvin <colvin@fr.com>; Kenneth Darby
`<kdarby@fr.com>
`Subject: RE: IPR2018-01670, -01676, -01678, -01679, -01680, and -01682 - for motion to strike/sur-
`surreply
`
`Your Honors:
`
`Mylan requested (see below) to strike Sanofi exhibit 2319 and accompanying portions of the surreplies:
`IPR2018-01670 at 12
`IPR2018-01676 at 7
`IPR2018-01678 at 6
`IPR2018-01682 at 9
`
`Sanofi contacted the Board and offered to withdraw EX2319, but not the corresponding portions of the
`surreplies (see below).
`
`Sanofi’s offer does not remedy the problem, it exacerbates it. Without the exhibit, the Board will not be
`able to see why the citing portions of the surreplies are so wrong. If the improper declaration and
`accompanying portions of the surreplies are not struck, Mylan should be permitted an opportunity to
`cross examine Mr. Veasey and file a sur-surreply.
`
`Although the Veasey declaration remains in the record, Sanofi declines to make Mr. Veasey available for
`cross examination.
`
`The parties are available for a call with the Board today (11/14) or after 1 pm Eastern on Monday
`(11/18).
`
`Respectfully,
`Richard Torczon
`Reg. No. 34,448
`Counsel for Mylan
`
`From: Desai, Anish <anish.desai@weil.com>
`Sent: Friday, 8 November 2019 14.16
`To: trials@uspto.gov
`Cc: Josh Griswold <griswold@fr.com>; Torczon, Richard <rtorczon@wsgr.com>; IPR28328-0010IP1
`<IPR28328-0010IP1@fr.com>; Derryberry, Wes <wderryberry@wsgr.com>; Thomas, Tasha
`<tthomas@wsgr.com>; Carsten, Douglas <dcarsten@wsgr.com>; Guise, Jeff <JGuise@wsgr.com>;
`
`IPR2018-01676, -01678, -01680
`Ex. 3002 p. 1 of 3
`
`

`

`Dykhuis, Arthur <adykhuis@wsgr.com>; Steiner, Ellie <esteiner@wsgr.com>; Chu, Franklin
`<ychu@wsgr.com>; Westin, Lori <lwestin@wsgr.com>; Stafford, Nicole <nstafford@wsgr.com>;
`JWong@winston.com; PfizerIPRs@winston.com; Ansley, Sutton <sutton.ansley@weil.com>; Karl Renner
`<renner@fr.com>; John S. Goetz <Goetz@fr.com>; Matt Colvin <colvin@fr.com>; Kenneth Darby
`<kdarby@fr.com>
`Subject: RE: IPR2018-01670, -01676, -01678, -01679, -01680, and -01682 - for motion to strike/sur-
`surreply
`
`Dear Trial Board,
`
`After further consideration, and in response to Petitioner’s email below, Patent Owner will agree to
`expunge Ex. 2319. Mr. Veasey’s declaration (Ex. 2319) was served as supplemental evidence on July 16,
`2019 in response to evidentiary objections made by Petitioner. As Petitioner has not yet filed a motion
`to exclude, the filing of this exhibit was not necessary. Patent Owner reserves the right to re-file the
`declaration in response to any motion to exclude filed by Petitioner.
`
`Respectfully submitted,
`Anish Desai
`Counsel for Patent Owner
`
`From: Torczon, Richard <rtorczon@wsgr.com>
`Sent: Thursday, November 7, 2019 3:50 PM
`To: Josh Griswold <griswold@fr.com>; trials@uspto.gov
`Cc: IPR28328-0010IP1 <IPR28328-0010IP1@fr.com>; Derryberry, Wes <wderryberry@wsgr.com>;
`Thomas, Tasha <tthomas@wsgr.com>; Carsten, Douglas <dcarsten@wsgr.com>; Guise, Jeff
`<JGuise@wsgr.com>; Dykhuis, Arthur <adykhuis@wsgr.com>; Steiner, Ellie <esteiner@wsgr.com>; Chu,
`Franklin <ychu@wsgr.com>; Westin, Lori <lwestin@wsgr.com>; Stafford, Nicole <nstafford@wsgr.com>;
`JWong@winston.com; PfizerIPRs@winston.com; Ansley, Sutton <sutton.ansley@weil.com>; Desai,
`Anish <anish.desai@weil.com>; Karl Renner <renner@fr.com>; John S. Goetz <Goetz@fr.com>; Matt
`Colvin <colvin@fr.com>; Kenneth Darby <kdarby@fr.com>
`Subject: IPR2018-01670, -01676, -01678, -01679, -01680, and -01682 - for motion to strike/sur-surreply
`
`Your Honors,
`
`Patent owner Sanofi submitted improper new exhibits with its surreplies in violation of the trial practice
`guide. In particular, petitioner Mylan seeks to strike EX2319 (Veasey declaration) and corresponding
`portions of the surreplies in IPR’1670, IPR’1676, IPR’1678, and IPR’1682. Mylan also seeks to strike new
`argument in IPR’1679 (on pp. 4-5, 13-14) and IPR’1680 (pp. 8-9). The affected portions have already
`been identified to Sanofi.
`
`In the alternative, Mylan seeks authorization for a sur-surreply in these cases to address the new
`argument and to provide a briefing opportunity after cross-examining Mr. Veasey.
`
`Sanofi opposes these requests.
`
`The parties are available a call at Friday, 11/8, after 2 ET; Monday, 11/11, before 2 ET; and Tuesday,
`11/12, after 2 ET. Please note that Sanofi has a pending request for a call (below) for the same times.
`
`IPR2018-01676, -01678, 01680
`Ex. 3002 p. 2 of 3
`
`

`

`Respectfully,
`Richard Torczon
`Counsel for Mylan
`
`IPR2018-01676, -01678, -01680
`Ex. 3002 p. 3 of 3
`
`